Maria E. Arcila, MD, as a molecular genetic pathologist, she works primarily involves the study and detection of genetic changes in cancer tissue. These changes can be used to diagnose and confirm the presence of individual cancer types and help tailor patient-specific treatment, determine patients’ prognosis and risk of recurrence, and monitor their disease once they start therapy. As a hematopathologist, she works closely with our clinical colleagues to diagnose diseases that affect the blood and the lymphoid systems. Dr. Arcila directly examines tissue and blood samples to diagnose, stage, and monitor hematologic cancers including leukemia, lymphoma, myeloma, and other diseases at both the morphologic and the molecular levels. Her research is focused on the molecular changes that fuel the development of lung carcinoma and the search for possible therapeutic and prognostic markers in patients with this disease. Because of this interest, she has become directly involved with the expansion, validation, and implementation of clinical tests at Memorial Sloan Kettering to detect mutations relevant to the management and treatment of patients with lung carcinoma.
Stephan Beck, PhD, FMedSci, is Professor of Medical Genomics at the University College London (UCL) Cancer Institute. Using experimental and computational approaches, his laboratory has broad interests in the genomics and epigenomics of phenotypic plasticity in health and disease. He has over 30 years experience in high-throughput genomics and has (co)authored over 250 publications that have attracted over 50,000 citations to date. He received his PhD in 1985 from the University of Konstanz where he studied DNA structure. After appointments at the MRC Laboratory of Molecular Biology in Cambridge, Millipore Corporation in Boston and the Imperial Cancer Research Fund in London, he joined the Wellcome Trust Sanger Institute in 1996. During his tenure as Head of Human Sequencing (1998-2006), he played a leading role in the sequencing and analysis of the human, mouse and zebrafish genomes. He is founding member of the Human Epigenome Project and the UK Personal Genome Project and serves on numerous national and international advisory boards. He is a Fellow of the Academy of Medical Sciences and recipient of a Royal Society Wolfson Research Merit Award.
Dieter Beule, PhD, studied in Freiburg, Sussex and Berlin and obtained his PhD in theoretical physics. Since more than twenty years he has been working in interdisciplinary biomedical data analysis projects and contributed to advance molecular biological high throughput technologies into clinical application. In 2015 he joined the Berlin Institute of Health to build up the bioinformatics core unit. Prior to joining the BIH he co-founded and managed two companies in the fields of bioinformatics services and medical device software.
Alexis B. Carter, MD, FCAP, FASCP, is the Director of Pathology Informatics for Children's Healthcare of Atlanta. She is the first chair of the new Informatics Subdivision in the Association of Molecular Pathology and also serves as a member of the AMP Governing Board, as the Test Directory Editor and as a member of the Publications Committee. She is a past-president of the Association of Pathology Informatics and is a member of the Informatics Committee and Clinical Informatics Steering Committee of the College of American Pathologists. She is the immediate past-chair of the International Pathology and Laboratory Medicine Special Interest Group (IPaLM SIG) of SNOMED CT International which is the governing body for SNOMED CT Terminology. She is the secretary for the working group on two-dimensional barcoding for the Clinical and Laboratory Standards Institute, is a section editor for informatics for Archives of Pathology and Laboratory Medicine and is on the editorial board of the Journal of Pathology Informatics. She is board-certified in Anatomic Pathology, Clinical Pathology, Molecular Genetic Pathology and Clinical Informatics, and her clinical practice is in both clinical informatics and molecular genetic pathology.
Rossa W.K. Chiu, MBBS, PhD, is the Choh-Ming Li Professor of Chemical Pathology and Assistant Dean (Research) at the Faculty of Medicine, The Chinese University of Hong Kong. She is an Honorary Consultant Chemical Pathologist at the New Territories East Cluster of Hospitals, Hong Kong. Prof Chiu’s research focuses on the development of novel disease diagnostic approaches. She has developed non-invasive methods based on maternal blood analysis for the prenatal assessment of Down syndrome which has led to a worldwide change in clinical practice. Recently, she has been investigating the detection of cancer-derived DNA in human plasma with an aim to develop non-invasive blood tests for the early detection of cancer. To date, Prof Chiu has published over 140 peer-reviewed research articles and has over 170 granted patents or patent applications. Prof Chiu has received a number of awards for her research, including the 2012 China Women in Science Fellowship, the 2013 American Association of Clinical Chemistry Outstanding Scientific Contributions for a Young Investigator and the 2016 Croucher Senior Medical Research Fellowship. She is currently a member of the Board of Directors of the International Society of Prenatal Diagnosis. She was the President of the Hong Kong Society of Clinical Chemistry between 2004 to 2005.
Manfred Dietel, is currently Medical Director of the Institute of Pathology and former Head of the Board of Directors at the Charité University Hospital in Berlin, Germany. He previously served as Dean of the Medical Faculty at Charité. Before this, Prof. Dietel was the Director of the Institute of Pathology at the University of Kiel, Germany. He received his medical education from the University of Hamburg, Germany, where he was promoted to Assistant Professor and also served as a full Professor of anatomical and surgical pathology.
Professor Dietel’s scientific interests include in vitro cell growth of benign and malignant tumours of gastro-intestinal, ovarian and mesenchymal origin, prognosis of ovarian tumours, molecular mechanisms of cytostatic drug resistance, molecular tumour pathology, telepathology, and predictive biomarkers. Methods of interest are cell culture, immunohistochemistry, in-situ hybridisation, PCR, molecular pathology, next generation sequencing and telecommunication in diagnostic and scientific pathology.
Professor Dietel is on the editorial board of several scientific journals and the editorial board of the WHO Classification of Tumours series: Pathology and Genetics of Gynaecological Tumours. He was president of the Congress of the European Society of Pathology (2001) and head of the annual meeting of the German Society of Senology (2001). He is a member of several national and international scientific societies including the American Association of Cancer Research (AACR), the European Society of Pathology (ESP), and the German Society of Pathology (DGP), where he is the Past-President. His member of the Leopoldina - German National Academy of Science.
Per Guldberg, PhD, is a professor and group leader at the Danish Cancer Society Research Center. He has a background in human genetics and obtained his PhD in 1996. He then became a postdoctoral fellow at the Danish Cancer Society and was promoted to group leader in 2002 and research professor in 2004. His laboratory has a long-standing interest in the genetic and epigenetic alterations that drive cancer development, with a focus on the potential of DNA testing for early and non-invasive detection of cancer. Recent work includes the development of urine-based tests for high-sensitivity detection of bladder cancer and other genitourinary cancers.
Mike Hubank, PhD, Michael Hubank, PhD, is a Senior Research Scientist at the Royal Marsden Hospital, with an honorary Readership in Genomics at the Institute for Cancer Research, London. He leads the Molecular Diagnostics Translational Research team, establishing new genomics assays, and developing and applying diagnostic testing for clinical trials and research studies across the cancer field. Dr Hubank previously led UCL Genomics for 16 years, contributing to many publications in fields ranging from cancer to metagenomics. He is particularly interested in implementing genomic testing for circulating tumour DNA in a clinically relevant setting.
Bernhard Küster, PhD, conducts research in the field of chemical and functional proteomics. This research focuses on a range of questions relating to how proteins interact with each other and with active pharmaceutical ingredients, which molecular mechanisms play a role in cancer and how these can be used for individual approaches to clinical treatment. He uses chemical and biochemical methods as well as spectroscopic and bioinformatic high throughput technologies. After studying chemistry at the University of Cologne, Professor Küster obtained his doctorate in biochemistry at the University of Oxford. He subsequently worked as a postdoctoral researcher in Heidelberg, Germany, and Odense, Denmark. Prior to becoming a full professor at TUM and until 2007 he was Vice President of Cellzome AG, a Heidelberg-based biotech company. Professor Küster is the Chair of the TUM Department of Biosciences and a member of the Graduate School Experimental Medicine. His research is funded by the Center for integrated Protein Science Munich (CiPSM), the German Consortium for Translational Cancer Research (DKTK) and the pharmaceutical industry. Professor Küster is one of the founders of the biotech company OmicScouts GmbH.
Stephen E. Lincoln, is responsible for scientific collaborations and clinical studies at Invitae. He has over 25 years experience in bioinformatics, specifically as it is applied in the fields of genetics and genomics. His most recent research include studies of the clinical validity and utility of expanded genetic testing in hereditary cancers (PMIDs 26270727 and 26207792). He also works on rigorous methods to assess analytic validity of new assays and algorithms. Previously he held senior positions at Complete Genomics, Affymetrix and Incyte Genomics. Steve's academic background includes 7 years with Eric Lander at the Whitehead Institute and MIT during the initial phases of the human genome project.
Neal I. Lindeman, MD, interests and activities cover diverse subspecialties of pathology, including molecular diagnostics, pulmonary pathology, and clinical chemistry. Dr. Lindeman, alongside oncologists and scientists at the Dana-Farber Cancer Institute (DFCI), demonstrated, in a 2004 publication in Science, the association between somatic mutations of EGFR and dramatic response to therapy with targeted EGFR inhibitors in advanced lung cancer. This discovery led to new therapies that prolong survival from ~16 weeks to ~2 years for 20% of patients with advanced lung adenocarcinoma, and has laid the basis for further clinical and basic scientific studies, at Harvard and beyond. Dr. Lindeman continued as lead pathologist on related projects, leading to scores of additional co-authored publications in lung cancer during the past decade, including the publication of an international practice guideline for molecular analysis of lung cancer. Dr. Lindeman is Director of the Brigham and Women's Hospital (BWH) Molecular Diagnostics Lab, which pioneered the implementation of EGFR mutation testing into clinical practice in 2004. Subsequently, Dr. Lindeman has been performing comprehensive genomic sequencing for all cancers under a program called PROFILE jointly sponsored by BWH, DFCI and Boston Children's Hospital (BCH). The PROFILE program performs hybrid capture next generation sequencing for 309 genes of all cancer patients, approximately 5000 per year. Beyond Harvard, Dr. Lindeman participates in leadership of the Association for Molecular Pathology, the College of American Pathologists, and the American Association of Clinical Chemistry, currently chair of the Molecular Pathology Division.
Christina Lockwood, PhD, DABCC, DABMGG, is an Assistant Professor and Associate Director of the Genetics and Solid Tumors Laboratory at the University of Washington. She is a Diplomate of the American Board of Clinical Chemistry and the American Board of Medical Genetics and Genomics. After obtaining her PhD at the University of Wisconsin, Dr. Lockwood completed postdoctoral fellowship training in Clinical Chemistry and Clinical Molecular Genetics at the Washington University School of Medicine in St. Louis, MO. Dr. Lockwood has been active in designing and clinically implementing targeted next-generation sequencing assays to guide personalized treatment decisions in oncology. She has also been involved in developing new diagnostic methods based on circulating cell-free nucleic acids in genetics and oncology. Dr. Lockwood's translational research focuses on the discovery of genetic alterations in tumorigenesis using integrative high-complexity bioinformatic approaches to interrogate the genomes of patients with both solid tumor and hematologic malignancies.
Manja Meggendorfer, MD, MBA, is a leading scientist in the department of molecular genetics of the MLL Munich Leukemia Laboratory. There she is responsible for research and development with emphasis on Next generation sequencing in leukemia diagnostics. She studied biology at the universities in Tübingen and Munich with focusing on human genetics, immunology and bioinformatics. She received her master of science in Biology from the Ludwig-Maximilians-University in Munich and her PhD in collaboration with the Helmholtz Center Munich working on gene regulation within the architecture of the cell nucleus. After her post doc period in 2011 she shifted to the field of hematology as scientist in the department of molecular genetics at the MLL Munich Leukemia Laboratory under the supervision of Prof. Torsten Haferlach. Beside leukemia diagnostics her scientific work focuses on mutational patterns and their prognostic impact within different leukemia entities. She published already more than 30 papers in hematology in the last 5 years. In combination with her MBA in Health Care Management the aim of her work is also to improve the diagnostic and prognostic wrap-up and to optimize routine diagnostic approaches for patients with leukemia or lymphoma.
Melissa B. Miller, PhD, D(ABMM), is a Professor of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill School of Medicine. She is also the Director of the Clinical Molecular Microbiology Laboratory and Associate Director of the Microbiology-Immunology Laboratory for UNC Health Care. She received her Ph.D. in Molecular Biology from Princeton University and completed the Medical and Public Health Microbiology Fellowship at UNC. Dr. Miller has broad research interests spanning from MRSA epidemiology to accurate and cost-effective molecular detection of mycobacterial and viral infections. She is particularly interested in the assessment of patient and healthcare outcomes associated with the implementation of new molecular technologies.
Aleksandar Milosavljevic, PhD
Klaus Pantel, MD, is Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf. The institute is part of the Centre of Experimental Medicine and the University Cancer Center Hamburg (UCCH). The pioneer work of Prof Pantel in the field of cancer micrometastasis, circulating tumor cells and circulating nucleic acids (ctDNA, microRNAs) is reflected by more than 400 publications in excellent high ranking biomedical and scientific journals (incl. NEJM, Lancet, Nature Journals, Cancer Cell, Science Translational Medicine, Cancer Discovery, PNAS, JCO, JNCI, Cancer Res.) and has been awarded the AACR Outstanding Investigator Award 2010, German Cancer Award 2010, and ERC Advanced Investigator Grant 2011. Moreover, Prof Pantel coordinates the European TRANSCAN group “CTC-SCAN”, the European IMI consortium CANCER-ID (www.cancer-id.eu) on blood-based “Liquid Biopsies” and serves on the Editorial Boards of international cancer journals (e.g., Clin. Cancer Res., Breast Cancer Res., Cancer Res.).
Simon Patton, is currently Director of the European Molecular Genetics Quality Network (EMQN) – the global leader in the provision of External Quality Assessment (EQA) schemes to diagnostic laboratories in the fields of genetics and pathology. He trained at the University of Liverpool in marine biology, before doing his doctorate in Genetics at the University of Cambridge. He is currently at Central Manchester University Hospitals NHS Foundation Trust. Simon’s work has focussed on global improvement in the standards and quality of diagnostic laboratory testing – a field that he has worked in since 1999 through his involvement with the EMQN.
Harlan Robins, PhD, is Program Head of the Computational Biology group of the Fred Hutchinson Cancer Research Center (FHCRC) and member of the Public Health Sciences and Human Biology divisions. He obtained his bachelor’s degree at Harvard University as a physics major with a concentration in mathematics. He then obtained his Masters and Ph.D. in theoretical physics (string theory) from the University of California Berkeley with a visiting appointment to the California Institute of Technology (“Caltech”). Dr. Robins obtained a postdoctoral appointment in theoretical physics in the particle theory group at the Weizmann Institute of Science in Israel. Interested in the mathematics behind genetics and observing the potential utility of high-level mathematics to study problems in the biological sciences, Dr. Robins took another postdoctoral appointment at the Institute for Advance Study in Princeton to study under the famed biologist Dr. Arnold Levine. Working with Dr. Levine, Dr. Robins concentrated on developing bioinformatic algorithms for micro RNA targets and bacterial genome analysis, a precursor to his current faculty appointment. In 2009, he co-founded Adaptive Biotechnologies Corporation and now serves as the Chief Scientific Officer. In the same year Dr. Robins was the recipient of the Ellison Award from the Ellison Medical Foundation New Scholars Program to support new investigators of outstanding promise in the basic biological sciences. Dr. Robins was also granted the Keck Foundation Medical Research Award in 2010, along with Dr. Christopher Carlson, to support their work at the FHCRC in advanced DNA sequencing methods to measure past and present pathogenic exposure in humans.
Mark J. Routbort, MD, PhD, is a practicing molecular pathologist and bioinformatician at the University of Texas MD Anderson Cancer Center, where he develops and supports the computational pipelines for next generation sequencing in the clinical Molecular Diagnostics Laboratory. He is board certified in Anatomatic & Clinical Pathology, Hematology, and Clinical Informatics. Receiving a Master's degree in Biochemistry and Molecular Biology from the University of Chicago, and later his MD and PhD degrees at Duke University, he joined the faculty at MD Anderson in 2004, where he has focused his informatics efforts on initiatives directed at improving pathologist and lab workflow, and on improving the generation, storage, reporting, and retrieval of pathology and laboratory data. He currently serves as Director of Computational and Integrational Pathology for the Division of Pathology and Laboratory Medicine, facilitating the transactional and integrational use of genomic data both internally and with large scale multi-institutional collaborations like NCI-MATCH and AACR Project GENIE.
Somak Roy, MD, is Assistant Professor of Pathology at the University of Pittsburgh Medical Center (UPMC). He serves as the Director of Molecular Informatics and genetics Services at the Division of Molecular and Genomic Pathology at UPMC. Dr. Roy is a board-certified molecular and anatomic pathologist. His clinical and translational work focuses on the following; 1) Use of modern computational infrastructure and innovative software technology for high-throughput sequence analysis, genomic data visualization, and optimizing molecular laboratory workflow. 2) molecular characterization of urothelial carcinoma to identify clinically relevant, theranostic biomarkers. Since 2014, he has been a member of Informatics Subdivision in the Association of Molecular Pathology (AMP). He served as a representative to the Clinical Practice Committee from 2014-2016 and currently to the Program Committee. Dr. Roy is currently chairing the AMP workgroup that is developing guidelines for validation of clinical NGS bioinformatics pipeline.
Josef RüSchoff, MD, CMO of Targos Molecular Pathology where biomarker services have been provided within clinical approval trials for more than 10 years. One of the main testing expertises refers to HER2, e.g. within the HERA trial for adjuvant trastuzumab in breast cancer (Piccart-Gebhart MJ et al. NEJM 2005) and the ToGA trial for trastuzumab in advanced gastric and gastroesophageal junction cancer (Bang YJ et al. Lancet 2010). Background: After board certification and habilitation at the University of Marburg, Senior Pathologist and full Univ. Professor at Inst. of Pathology, Univ. of Regensburg. 1998-2007: Dir. Inst. of Pathology, Klinikum Kassel. Since 2007 CMO Inst. of Pathology Nordhessen and Targos Molecular Pathology GmbH. Since 2008 visiting Professor, Med. Faculty, Univ. Göttingen. (http://www.pathologie-nordhessen.de/de/PROF._DR._MED._JOSEF_RUeSCHOFF.html)
Mariangela Russo, PhD, is an expert in pharmacological screening and translational research in human tumors. In 2005 she graduated in Pharmaceutical Biotechnology at the University of Naples, Italy. In 2007 she went on to get her Masters in Cancer Pharmacy and Pharmacology, University of Milan, Italy. In 2010 she earned her PhD in Complex Systems in post-genomic Biology, University of Torino, as employee of Horizon Discovery Ltd, Italy. She currently is the Senior Post Doc at Molecular Oncology Lab at IRCCS Candiolo- Turin.
Avni B. Santani, PhD, is a Director in the Division of Genomic Diagnostics at the Children’s Hospital of Philadelphia and Assistant Professor of Clinical Pathology at the University of Pennsylvania, where she oversees the clinical exome sequencing program for rare pediatric disorders. Santani is an experienced leader in molecular diagnostics with over eleven years of experience in clinical testing, genomics, strategy and laboratory administration. Dr. Santani received her Master’s in Medical Molecular Genetics at the University of Aberdeen and her PhD in Genetics at Texas A&M University. She holds specialty board certifications in Clinical Molecular Genetics and Clinical Cytogenetics. In her current role, Dr. Santani has overseen the development and implementation of diagnostic tests for over 100 disease genes implicated in rare genetic disorders. Her primary focus is leveraging genomics for the diagnosis of rare genetic disorders. Her work in the area of clinical genomics led to her receiving the Innovator of the Year Award (2015) by the Philadelphia Business Journal. She also is actively involved with several national working groups including a member of College of American Pathologists Next Generation Sequencing Project Team and The Association of Molecular Pathology Teaching and Education Committee.
Haroun N. Shah, PhD, grew up in the Caribbean island of Trinidad. He obtained his PhD from the University of London in Microbial Biochemistry (1981) and was immediately appointed there. He has held senior academic appointments at universities for 35 years with intermittent periods (2-3 years) in Canada and the Middle East. In 1997, he took up his first appointment outside university as director, Molecular Identification Services Unit, Public Health England. He explored several cutting-edge technologies in Genomics and Proteomics for microbiology and co-organized 19 consecutive conferences in the field to showcase developments annually. The first, titled “Intact Cell MALDI” in October 1998, was the earliest meeting organized to explore microbial applications of MALDI-TOF MS (see “Mass Spectrometry for Microbial Proteomics”, Ed. H. N. Shah and S. E. Gharbia; Wiley 2010). The huge success of this technology is celebrated in recent books, “MALDI-TOF Mass Spectrometry in Microbiology” (Ed. M. Kostrzewa and S. Schubert. Caister Academic Press, 2016); Introduction, H. N. Shah; “A personal vision of the MALDI-TOF MS journey from obscurity to frontline diagnostics” and in our forthcoming book, “MALDI-TOF and Tandem MS for Clinical Microbiology” (Ed. H. N. Shah and S. E. Gharbia, Wiley 2017) in which the author write/co-writes 8 of the 21 chapters. In September 2015, the author took up a chair in the Department of Natural Sciences, Middlesex University, London and is currently expanding his interest into diverse areas of microbiology where proteomics and mass spectrometry are having an incisive impact into elucidating key processes in the biology of the cell.
Darryl K. Shibata, MD, is a Professor of Pathology at the University of Southern California Keck School of Medicine and a member of the Norris Comprehensive Cancer Center. He has studied the molecular genetics of human colorectal cancers and is especially interested in inferring tumor ancestry.
Albrecht Stenzinger, MD, is the head of the IPH Center for Molecular Pathology at the Institute of Pathology, University Hospital Heidelberg, Germany. He is holding an MD degree from the University of Giessen (Germany), completed his residency in pathology at the Charité University Hospital in Berlin and the University Hospital Heidelberg (Germany) and is a board certified surgical pathologist and senior attending. Albrecht received postdoctoral training at the University of Heidelberg, Germany and Massachusetts General Hospital/Harvard Medical School, USA. He has a broad expertise in molecular pathology and works in the field of tumor genetics and molecular diagnostics.
Gregory A. Storch, MD, is the Ruth L. Siteman Professor of Pediatrics and Professor of Medicine and of Molecular Microbiology at Washington University School of Medicine, the Director of the Division Pediatric Laboratory Medicine, and the Medical Director of Clinical Laboratories at St. Louis Children’s Hospital. He received his AB degree from Harvard College and his MD from NYU School of Medicine. After completing medical school, he was an intern and resident in internal medicine at the Jewish Hospital of St. Louis. Following his residency, he spent two years working for the Centers for Disease Control as an Epidemic Intelligence Service Officer, stationed in the Louisiana Department of Health in New Orleans. He then did an infectious disease fellowship at Washington University. After completing his fellowship in 1981, he joined the faculty in the Department of Pediatrics of the Washington University School of Medicine, where he has been ever since. Dr. Storch’s research interests are in molecular diagnosis of infectious diseases, the human virome, and pathogen discovery. He also serves as Medical Director of Project ARK, an umbrella organization that provides medical and support services for children, youth, women, and families affected by HIV.
Aik Choon Tan, PhD, is an Associate Professor of Bioinformatics and Director of the Translational Bioinformatics and Cancer Systems Biology Laboratory in the Division of Medical Oncology, Departments of Medicine, Biostatistics and Informatics, University of Colorado Anschutz Medical Campus. He is also the co-Director of the Biostatistics and Bioinformatics Core for the Colorado Lung Cancer SPORE, and is the Director of the Graduate Certificate of Biomedical Data Science. He obtained his B.Eng. in Chemical/Bioprocess Engineering from the University of Technology Malaysia and earned his Ph.D. in Computer Science/Bioinformatics from the University of Glasgow. He then received his post-doctoral training at the Johns Hopkins University Whiting School of Engineering and at the Sidney Kimmel Cancer Center at the Johns Hopkins University School of Medicine. He joined the faculty of University of Colorado in 2009. His lab develops and applies computational/machine learning and statistical methods to integrate high-throughput and complex biological data sources for 1) biomarker discovery; 2) understanding the resistance mechanisms in tumors; and 3) drug repurposing and repositioning. He collaborates closely with his clinical colleagues in translating bioinformatics and bench discovery to clinical trials
Janis M. Taube, MD, MSc, s the Director of Dermatopathology Division and Fellowship at Johns Hopkins University SOM. Dr. Taube’s research interests center on the immune evasion by solid tumors, specifically studying the PD-L1/PD-1 axis, and the identification of potential biomarkers of response to novel immunotherapies. This requires a focus on immunohistochemical and molecular methods for identifying cell surface antigens and signaling pathways in paraffin-embedded tissue. Dr. Taube’s lab described PD-L1-mediated adaptive immune resistance by melanoma, a finding which has now been extended to other tumor types. She also developed a robust IHC assay and methods of interpretation for studying PD-L1 as it relates to therapeutic response, and versions of this assay are now FDA approved. Her ongoing laboratory efforts focus on further characterizing the local, pre-treatment tumor microenvironment with the aim of developing rational treatment combinations and improving on patient selection algorithms.
Christian Thiede, MD, is a scientist with 25 years of research experience in the field of molecular analysis of human tumors, especially in the field of leukemia and lymphoma. After finishing his medical education at the FU Berlin, he had three years of Post-Doctoral training in the Department for Hematology and Oncology at Humboldt University/Charité, Berlin where he worked on the molecular characterization of gastric marginal zone B-cell lymphoma of MALT. He then went to Dresden to build up a research group and a diagnostic laboratory at the newly established Medical Faculty at the University of Technics in Dresden. Since 2006, he holds a position as professor for Molecular Hematology at Medical Faculty Carl Gustav Carus, University of Technics Dresden. His major focus is the understanding of the molecular mechanisms involved in leukemogenesis, alterations involved in treatment resistance, as well as the use of this information to perform targeted treatment and molecular monitoring of treatment response. In the recent four years, his groups has focused on the use of different Next-Generation Sequencing platforms to perform Whole Exome sequencing as well as amplicon resequencing for the characterization of leukemic samples from patients with acute myeloid leukemia.
James Versalovic, MD, PhD, received his M.D. with Honors at Baylor College of Medicine (BCM) in 1995 and his Ph.D. in Cellular and Molecular Biology at BCM in 1994. He pursued clinical pathology/medical microbiology residency training at the Massachusetts General Hospital and Harvard Medical School. He also received postdoctoral research training in the Division of Comparative Medicine at the Massachusetts Institute of Technology (MIT). Dr. Versalovic joined the medical staff as a clinical pathologist at the Massachusetts General Hospital and served as Assistant Professor of Pathology at Harvard Medical School from 1999-2001. He is board-certified in clinical pathology, molecular genetic pathology, and molecular diagnostics. Dr. Versalovic currently serves as Pathologist-In-Chief and as member of the Board of Directors at Texas Children’s Hospital. He also serves as Vice Chair of Pathology & Immunology at BCM, and Director of the Texas Children’s Microbiome Center. He holds the Milton J. Finegold endowed chair as Professor of Pathology & Immunology, and is Professor of Pediatrics, Molecular and Human Genetics, and Molecular Virology & Microbiology at Baylor College of Medicine. He is Co-Director of the Medical Scientist (MD/PhD) Training Program at Baylor. He served as Editor-in-Chief of the Manual of Clinical Microbiology and Editor of Therapeutic Microbiology: Probiotics and Related Strategies. As a Principal Investigator, his primary research interests include the human microbiome, probiotics, medical and molecular microbiology, gastrointestinal microbiology, and digestive diseases. His research program has been supported by the U.S. National Institutes of Health, Department of Defense, and Crohn’s and Colitis Foundation of America. Dr. Versalovic has authored 140 primary manuscripts, 34 book chapters, and 2 patents. He received the Lansky Award as a national leader in pathology under the age of 45 from the College of American Pathologists Foundation. He also received the BioGaia Ivan Casas Probiotics Research Award and the BCM Graduate School of Biomedical Sciences Distinguished Alumnus Award. He currently is President of the Association of University Pathologists (Pluto Society).
Andreas von Deimling, MD, received his basic medical education in the city of Freiburg, Germany. Clinical training began with a first residency at the University Hospital Zurich, Switzerland, in 1988 followed by a research program in the Neuro-Oncology Department of the Massachusetts General Hospital from 1990 to 1992. Neuropathology training was completed in the Department of Neuropathology at the University of Bonn from 1992 to 1994. From 1995 to 1988 he served there as consultant and was awarded the “Schäfersnolte Award” and the endowed “Schilling Professorship”. In 1998, he was appointed as Director of Neuropathology at the Charité, Humboldt University, in the city of Berlin. This was followed by relocation to the city of Heidelberg in 2007, accompanied by a combined appointment as director of Neuropathology at the University of Heidelberg and director of the Clinical Cooperation Unit Neuropathology at the German Cancer Institute. His scientific focus is on molecular tumor neuropathology with special attention to developing diagnostic tools and algorithms. This included the mutation specific antibodies H09 targeting the IDH1-R132H and VE1 targeting the BRAF-V600E mutations. Current work includes establishing a CpG methylation based brain tumor classification and Next Generation Sequencing as routine tools in diagnostic Neuropathology. He is a member of the European Academy of Cancer Sciences and was awarded the “Deutsche Krebspreis “ in 2016.
Magnus von Knebel Doeberitz, MD, is Professor of Molecular Oncology and Medical Director of the Department of Applied Tumor Biology, Institute of Pathology of the University of Heidelberg. He is also head of the Clinical Cooperation Unit G105 of the German Cancer Research Center and is affiliated with the Molecular Medicine Partner Unit of the European Molecular Biology Laboratory (EMBL). He further served as founder and board member of several biotech companies, including mtmlabs (www.mtm-labs.com) that was acquired by Roche for 190 Mio € in 2011. He has been and still is medical and scientific adviser to several pharmaceutical companies. Magnus von Knebel Doeberitz received his academic education from the medical schools of Ghent in Belgium, Hamburg, Freiburg, and Kiel in Germany, and from Penn State University, Hershey, PA, USA. 1985 to 1994 he spent his post doc at the Department of Applied Tumour Virology, German Cancer Research Center in the group of Nobel laureate Harald zur Hausen. 1995 to 2001 he served as Professor of Molecular Oncology and Head of the Section of Molecular Diagnostics and Therapy in the Department of Surgery, University of Heidelberg. 2001 he was appointed as Medical Director of the Department of Applied Tumour Biology at the Institute of Pathology, University of Heidelberg. His major scientific interests relate to mechanisms of human carcinogenesis by papillomaviruses and DNA mismatch repair deficiency, the identification of novel diagnostic markers and potential therapeutic targets as well as their clinical validation and translation into routine medical care. His current major activities are focussed on the clinical validation of two novel cancer vaccines. He published more than 220 peer- reviewed articles. He is Associate Editor of the International Journal of Cancer and member of the Editorial Boards of various journals including Disease Markers, Journal of Cancer Research and Clinical Oncology, and The Cyto Journal. He received numerous scientific awards including the Ernst von Leyden Award for Cancer - Early Detection and Prevention in 1998, the Christoph- Wilhelm Hufeland Award for Cancer - Early Detection and Prevention in 2000, the Distinguished Service Award of Cervical Cancer
Peter Wild, MD, is a senior consultant at Institute of Pathology and Molecular Pathology, University Hospital Zurich. He holds an academic rank of Professor of Systems Pathology, University of Zurich. Since January 2017, he is also Chief Scientific Officer (CSO) of the Foundation Medicine Lab at the University Hospital Zurich. His research focuses on molecular genetics of solid tumors. He has successfully established NGS technologies for diagnostic molecular pathology, and oranizes the Molecular Tumorboard Zurich (MTBZ). He completed his Pathology residency from the University of Regensburg, Hamburg-Eppendorf and Zurich in 2008. He has completed a postdoctoral training in Medical Biometrics at the University of Heidelberg, Germany. For a two year postdoctoral training in cell biology, he joined the lab of Willy Krek at ETH Zurich. In April 2010 he also received his Venia Legendi in Pathology from the University of Zurich. He receives funding for research from the European Commission (H2020, PrECISE), Oncosuisse and the Swiss National Science Foundation. He has been honored with various awards during his training and career, including the Rudolf-Virchow-Prize of the German Society of Pathology in 2013. Dr. Wild has co-authored more than 155 articles in peer-reviewed journals.
Axel zur Hausen, MD, PhD, received his M.D. at the University of Freiburg, Germany, in 1994. He started his residency of pathology at the University Hospital Zürich, Switzerland, and continued pathology training at the University Hospital Düsseldorf, Germany, and at the Free University Amsterdam, The Netherlands. He received his Ph.D. on the role of Epstein-Barr virus (EBV) in gastric cancer in 2004 at the Free University Amsterdam. In the same year he was appointed Full Professor at the University of Freiburg, Germany. In 2010 he was appointed as chairman and Professor of the Department of Pathology at the Maastricht University Medical Center, The Netherlands. His scientific focus is on the role of tumor viruses in human cancers. He reported the first detection of an EBV oncogene, i.e. BARF1, expressed in EBV-associated gastric carcinomas. By using comparative genomic hybridization he was the first to show that EBV-associated gastric carcinomas comprise a distinct subgroup of gastric carcinomas on the molecular level. In 2008 he focused on the recently detected Merkel cell polyomavirus (MCPyV) and published the first study on the presence of MCPyV in a larger number of Merkel cell carcinomas (MCC). In 2011 his group succeeded to prove the presence of MCPyV in a significant subset of chronic lymphatic leukemia. Current work addresses the role of the recently discovered human polyomaviruses in lymphomas and skin cancers. In addition, he works on the yet unidentified cellular origin of Merkel cell carcinoma, which he considers to originate from early B cells.